{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T18:33:31Z","timestamp":1759602811696},"reference-count":18,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T00:00:00Z","timestamp":1407283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the safety and efficacy of abiraterone acetate and prednisolone in <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>orean and <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>aiwanese patients with metastatic castration\u2010resistant prostate cancer not responding to docetaxel\u2010based chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this single\u2010arm study, 82 metastatic castration\u2010resistant prostate cancer patients who failed docetaxel\u2010based chemotherapy were treated with abiraterone (1000\u2009mg, once daily) and prednisolone (5\u2009mg, twice daily). Patients achieving a prostate\u2010specific antigen decline \u226550% were considered as responding.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 35 patients (43%) achieved prostate\u2010specific antigen response (95% confidence interval 32\u201354). The median time to prostate\u2010specific antigen progression was 4.7\u2009months (95% confidence interval 3.7\u20138.3); the median overall survival was 11.8\u2009months. Two (4%) of 50 patients with measurable disease achieved partial response. The median testosterone concentration was in the castration range (1.21\u2009nmol\/L) throughout the treatment period. Median dehydroepiandrosterone sulfate decreased from 0.725\u2009\u03bcmol\/L (baseline) to 0.080\u2009\u03bcmol\/L (cycle\u20094). The most common adverse event was bone pain (20%); grade\u20093\/4 adverse event of special interest were hypokalemia (7%), fluid retention and liver function abnormalities (5% each), hypertension (2%), and cardiac disorders (1%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A combination of abiraterone acetate and prednisolone appears to be a favorable second\u2010line treatment in <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>aiwanese and <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>orean patients with advanced metastatic castration\u2010resistant prostate cancer after failed docetaxel\u2010based chemotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/iju.12589","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T00:28:02Z","timestamp":1407371282000},"page":"1239-1244","source":"Crossref","is-referenced-by-count":10,"title":["Abiraterone acetate and prednisolone for metastatic castration\u2010resistant prostate cancer failing androgen deprivation and docetaxel\u2010based chemotherapy: A phase\u2009<scp>II<\/scp> bridging study in <scp>K<\/scp>orean and <scp>T<\/scp>aiwanese patients"],"prefix":"10.1111","volume":"21","author":[{"given":"Cheol","family":"Kwak","sequence":"first","affiliation":[{"name":"Department of Urology Seoul National University Hospital  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony Tong Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Urology Kaohsiung Veterans General Hospital  Kaohsiung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Moo","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology Samsung Medical Center Sungkyunkwan University School of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsi Chin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology China Medical University Hospital China Medical University  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Joon","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Urology Yonsei University College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen Chuan","family":"Ou","sequence":"additional","affiliation":[{"name":"Taichung Veterans General Hospital  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Soo","family":"Byun","sequence":"additional","affiliation":[{"name":"Department of Urology Seoul National University Bundang Hospital  Seongnam Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyou Young","family":"Rhim","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Raritan New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thian","family":"Kheoh","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Raritan New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wan","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Raritan New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Yeh","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Raritan New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret K","family":"Yu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development  Raritan New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choung Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Urology College of Medicine University of Ulsan Asan Medical Center  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/13685530412331284687"},{"key":"e_1_2_8_3_1","unstructured":"Bureau of Health Promotion Department of Health The Executive Yuan Taiwan.Cancer Registry Annual Report 2009 Taiwan published February 2012."},{"key":"e_1_2_8_4_1","unstructured":"Taiwan Cooperative Oncology Group (TCOG) National Health Research Institutes [NHRI].Taiwan Prostate Cancer Guideline 3rd edn. October 2010."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.45.1.1"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2013.45.3.162"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0642"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9259"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3781"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601879"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(94)90131-7"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3667"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.6819"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.1281"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3461"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810083391504"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/aja.2011.121"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.12589","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.12589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T17:13:35Z","timestamp":1696266815000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.12589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,6]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1111\/iju.12589"],"URL":"https:\/\/doi.org\/10.1111\/iju.12589","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,6]]}}}